FOR IMMEDIATE RELEASE:

AMERICAN BIO MEDICA REALIZES EXPONENTIAL GROWTH IN PUBLIC SECTOR CLIENT BASE
Government Sales Presence Increases "At Least Fivefold" in Past Three Months

KINDERHOOK, NY -- August 16, 2024 -- American Bio Medica Corporation (NASDAQ: ABMC) today reported that its sales presence in the public sector on-site drug testing market has increased significantly within the past 12 weeks, with product orders received from more than 12 new government-based clients.

ABMC chairman and chief executive officer Robert L. Aromando Jr. cited the company's direct sales efforts and new business plan as catalysts for the expanding sales base.

"As outlined in our three-year business plan, we are pursuing various avenues to expand our customer base, including strengthened distributor relationships, complemented by focused direct selling to high-profile customers and government agencies," said Aromando. "We are now beginning to realize the benefits of these efforts - specifically the efforts of our new business development directors. Our public sector sales have jumped at least fivefold in the past three months."

ABMC experienced strongest public sector growth in the South, Midwest, and Far West regions. Among the organizations that have initiated ordering from ABMC within the past three months are: the Arkansas Department of Corrections; Little Rock, Arkansas, Probation and Pretrial Services; Federal Probation and Pretrial Services in St. Louis and Kansas City, Missouri; Federal Probation and Pretrial Services in Kansas; State of Nebraska Pretrial Services; State of Hawaii Adult Probation, Riverside County (California) Mental Health Services; Contra Costa County (California) Substance Abuse Services; US Pretrial Services - Los Angeles; The Salvation Army - Hawaii; Southern Alabama Federal Probation Services; Southern Mississippi Federal Probation Services; and Federal Probation Services, Southern and Eastern Tennessee.

Aromando noted that product performance was the key factor in opening new orders.

"When we have the opportunity to demonstrate the simplicity, accuracy, and reliability of Rapid Drug Screen™ in comparison to incumbent products, we have been able to make a compelling case for change," he said. "I am encouraged that ABMC's sales directors have been able to leverage product performance into new opportunities. These new contacts will translate into revenue that positively impacts our performance in ABMC's second quarter and beyond."

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical and educational markets. ABMC's Drug Detector™ identifies minute traces of illegal drugs on surfaces, while the company's Rapid Drug Screen tests individuals and is proven to correlate greater than 99% with the standard laboratory screening test.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Contact:
     American Bio Medica Corporation
     Melissa A. Decker, 800/227-1243
     Fax: 518/758-8171
     Email: melissa@americanbiomedica.com
     Internet: www.americanbiomedica.com